Key result
Lipid-lowering therapy in a real-world ACS cohort was frequently suboptimal, with 38.9% of patients achieving the previous LDL-C goal but failing to meet the new 2019 ESC/EAS target of <55 mg/dl.
Why the study?
The 2019 ESC/EAS guidelines recommended lower LDL-C targets for very high-risk patients, but attainment in real-world ACS populations in relation to lipid-lowering treatments was uninvestigated.
Population
221 ACS patients
Comparison
Different lipid-lowering treatment intensity categories
Design
Single-centre prospective observational cohort study
Follow-up
One year
Authors
Loading...
Real-world LDL-C target attainment lags post-event; leaves open optimal implementation strategies in very high-risk ASCVD.
Observational (n=221)
No
A significant treatment gap exists in achieving the stricter 2019 ESC/EAS LDL-C targets in ACS patients, highlighting the need for more aggressive lipid-lowering therapy intensification and combination therapies.
Farmakis et al. (2019) conducted an observational in Acute coronary syndrome (n=221). Lipid-lowering therapy vs. Lower intensity lipid-lowering therapy or no therapy was evaluated on Attainment of the new LDL-C goal (<55 mg/dl and ≥50% reduction from baseline). Lipid-lowering therapy in a real-world ACS cohort was frequently suboptimal, with 38.9% of patients achieving the previous LDL-C goal but failing to meet the new 2019 ESC/EAS target of <55 mg/dl.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: